Targeting the surface molecules expressed on malignant cells has been a hallmark of tumor immunotherapy and was clinically proven efficacious by one of the earliest monoclonal antibodies, trastuzumab, against Human Epidermal Growth Factor Receptor 2 (HER2) in breast cancer [1,2,3]. Here, ERBB2 is linked to breast cancer.